Related Experiment Video

Updated: May 24, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Cyclin dependent kinases in cancer: potential for therapeutic intervention

Miriam Canavese1, Loredana Santo, Noopur Raje

  • 1MGH Cancer Center, Boston, MA, USA.

Cancer Biology & Therapy
|February 25, 2012
PubMed

Insights

Cyclin-dependent kinases (CDKs) regulate cell cycle progression and are implicated in cancer. CDK inhibitors show promise for treating cancers, including Multiple Myeloma (MM), by halting cancer cell proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell cycle progression is tightly regulated by cyclin-dependent kinases (CDKs) and cyclins.
  • Dysregulation of cell-cycle control and aberrant CDK activity are hallmarks of many cancers.
  • Multiple Myeloma (MM), a plasma-cell malignancy, exhibits cyclin overexpression, suggesting CDK inhibition as a therapeutic strategy.

Purpose of the Study:

  • To review the main classes of CDK inhibitors.
  • To focus on their mechanisms of action.
  • To discuss the clinical and pharmacological implications of CDK inhibitors for cancer treatment, with a specific focus on MM.

Main Methods:

  • Literature review of CDK inhibitors.
  • Analysis of preclinical and early clinical data for CDK inhibitors in MM.
  • Examination of mechanisms of action and therapeutic potential.

Main Results:

  • CDK inhibitors are a promising strategy for cancer treatment, inducing proliferation arrest and apoptosis.
  • Specific D cyclins are overexpressed in MM, validating CDK inhibition as a target.
  • Several CDK inhibitors are under investigation in preclinical and early clinical studies for MM.

Conclusions:

  • CDK inhibitors represent a potential therapeutic approach for various cancers, including the currently incurable Multiple Myeloma.
  • Understanding the mechanisms and clinical implications of CDK inhibitors is crucial for advancing cancer therapy.
  • Targeting cell-cycle regulatory proteins offers a promising avenue for neoplastic disease treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...